{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:47Z","timestamp":1792057727531,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xops.2026.101358","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:53:32Z","timestamp":1786377212000},"page":"101358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I Randomized Study of SCAI-005 Ophthalmic Solution: Safety, Tolerability, and Pharmacokinetics in Healthy Korean Adults"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7098-4203","authenticated-orcid":false,"given":"Jueun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7819","authenticated-orcid":false,"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3363-1496","authenticated-orcid":false,"given":"Bo-Een","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-2833","authenticated-orcid":false,"given":"Ji Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2854-1128","authenticated-orcid":false,"given":"Mi","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyoung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-7682","authenticated-orcid":false,"given":"Sungpil","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xops.2026.101358_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.xops.2026.101358_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"10.1016\/j.xops.2026.101358_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.5.2.10","article-title":"VEGF and intraocular neovascularization: from discovery to therapy","volume":"5","author":"Ferrara","year":"2016","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.xops.2026.101358_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week outcomes from the phase 3 trials of Brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.xops.2026.101358_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-Year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.xops.2026.101358_bib6","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1038\/s41598-025-92832-w","article-title":"Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment","volume":"15","author":"Lee","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.xops.2026.101358_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bjo-2024-326152","article-title":"Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration","volume":"109","author":"Borrelli","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2026.101358_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.xops.2026.101358_bib9","first-page":"1289","article-title":"Anxiety and mood in patients receiving intravitreal injection","volume":"28","author":"K\u0131z\u0131lta\u015f","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.xops.2026.101358_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425247.4.4.371","article-title":"Novel approaches to retinal drug delivery","volume":"4","author":"Janoria","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.xops.2026.101358_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"issue":"22","key":"10.1016\/j.xops.2026.101358_bib12","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.xops.2026.101358_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"10.1016\/j.xops.2026.101358_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.10.14.23","article-title":"A novel eye drop formulation for potential treatment of neovascular age-related macular degeneration","volume":"10","author":"Huang","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"10.1016\/j.xops.2026.101358_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf J"},{"issue":"2","key":"10.1016\/j.xops.2026.101358_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.amjmed.2022.09.026","article-title":"Liver injury associated with Turmeric-A growing problem: ten cases from the drug-induced liver injury network [DILIN]","volume":"136","author":"Halegoua-DeMarzio","year":"2023","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.xops.2026.101358_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.xops.2026.101358_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajo.2022.07.025","article-title":"Risk, prevalence, and progression of glaucoma in eyes with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections","volume":"243","author":"Shah","year":"2022","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:24:09Z","timestamp":1792056249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666914526002964"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101358","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Randomized Study of SCAI-005 Ophthalmic Solution: Safety, Tolerability, and Pharmacokinetics in Healthy Korean Adults","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101358"}}